TDMS Study 05134-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
1,3 BUTADIENE (BUTADIENE)
NTP Experiment-Test: 05134-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
Facility: Battelle Northwest
Chemical CAS #: 106-99-0
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 70 70 70 70 90
Scheduled Sacrifice 20 20 20 20 20 10
Early Deaths
Moribund 10 10 14 31 37 46
Dead 3 7 11 8 12 33
Accident 1 1 1
Survivors
Terminal Sacrifice 37 33 24 11
Animals Examined Microscopically 70 70 70 70 70 90
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (66) (44) (41) (43) (49) (64)
Intestine Large, Cecum (68) (46) (46) (47) (57) (78)
Histiocytic Sarcoma 1 (1%)
Intestine Small, Duodenum (66) (45) (44) (46) (53) (72)
Adenoma 1 (2%)
Carcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Intestine Small, Ileum (68) (46) (43) (47) (55) (75)
Carcinoma 1 (2%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Intestine Small, Jejunum (67) (45) (44) (47) (54) (70)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Liver (69) (52) (51) (61) (61) (90)
Adenocarcinoma, Metastatic, Mammary Gland 1 (1%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Hemangiosarcoma 1 (1%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 1 (1%)
Hemangiosarcoma, Metastatic, Heart 10 (16%) 20 (22%)
Hemangiosarcoma, Metastatic, Skin 1 (2%) 1 (1%)
Hepatocellular Carcinoma 4 (6%) 5 (10%) 7 (14%) 9 (15%) 8 (13%) 1 (1%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 11 (16%) 10 (19%) 8 (16%) 10 (16%) 10 (16%) 2 (2%)
Hepatocellular Adenoma, Multiple 1 (1%) 1 (2%) 1 (2%) 5 (8%) 5 (8%)
Histiocytic Sarcoma 3 (4%) 2 (4%) 6 (12%) 3 (5%) 7 (11%) 4 (4%)
Leiomyosarcoma, Metastatic, Intestine Small 1 (2%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Sarcoma, Metastatic, Mammary Gland 1 (1%)
Page 2
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Carcinoma, Metastatic, Stomach 2 (2%)
Mesentery (12) (13) (16) (9) (15) (6)
Histiocytic Sarcoma 1 (11%)
Sarcoma, Metastatic, Mammary Gland 1 (17%)
Fat, Hemangiosarcoma, Metastatic, Heart 2 (13%) 1 (17%)
Fat, Hemangiosarcoma, Metastatic, Spleen 1 (17%)
Fat, Histiocytic Sarcoma 2 (13%) 2 (13%)
Fat, Leiomyosarcoma, Metastatic, Intestine
Small 1 (11%)
Fat, Leiomyosarcoma, Metastatic, Stomach 1 (7%)
Fat, Sarcoma, Metastatic, Skin 1 (8%) 1 (11%)
Fat, Sarcoma, Metastatic, Stomach 1 (17%)
Fat, Sarcoma, Metastatic, Uterus 1 (8%)
Fat, Squamous Cell Carcinoma, Metastatic,
Stomach 1 (17%)
Pancreas (69) (49) (47) (48) (59) (88)
Sarcoma, Metastatic, Mammary Gland 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%)
Acinus, Carcinoma, Metastatic, Ovary 1 (2%)
Acinus, Hemangioma 1 (2%)
Acinus, Histiocytic Sarcoma 2 (3%) 2 (4%)
Acinus, Leiomyosarcoma, Metastatic,
Intestine Small 1 (2%)
Acinus, Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Acinus, Sarcoma, Metastatic, Skin 1 (2%)
Acinus, Squamous Cell Carcinoma, Metastatic,
Stomach 2 (2%)
Salivary Glands (70) (49) (50) (49) (60) (89)
Stomach, Forestomach (70) (50) (57) (68) (70) (89)
Histiocytic Sarcoma 1 (1%)
Leiomyoma 1 (1%)
Leiomyosarcoma 1 (1%)
Sarcoma 1 (1%)
Sarcoma, Metastatic, Mammary Gland 1 (1%)
Squamous Cell Carcinoma 1 (2%) 1 (1%) 1 (1%) 7 (8%)
Squamous Cell Papilloma 2 (4%) 2 (3%) 4 (6%) 15 (17%)
Squamous Cell Papilloma, Multiple 1 (1%) 1 (1%)
Stomach, Glandular (69) (49) (58) (68) (68) (86)
Histiocytic Sarcoma 1 (1%) 1 (1%)
Sarcoma, Metastatic, Mammary Gland 1 (1%)
Squamous Cell Carcinoma, Metastatic, Stomach 3 (3%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (70) (50) (50) (59) (70) (90)
Adenocarcinoma, Metastatic, Lung 1 (2%)
Hemangiosarcoma 1 (2%) 22 (31%) 25 (28%)
Histiocytic Sarcoma 1 (1%) 2 (4%) 1 (2%) 1 (1%)
Sarcoma, Metastatic, Mammary Gland 1 (1%)
Pericardium, Leiomyosarcoma, Metastatic,
Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (70) (49) (48) (49) (60) (88)
Adenocarcinoma, Metastatic, Mammary Gland 1 (1%)
Adenoma 3 (5%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 1 (2%) 3 (5%) 2 (2%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Stomach 1 (1%)
Capsule, Adenoma 1 (1%)
Adrenal Gland, Medulla (70) (48) (47) (45) (60) (86)
Adenocarcinoma, Metastatic, Mammary Gland 1 (1%)
Histiocytic Sarcoma 1 (1%) 1 (2%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 2 (3%)
Sarcoma, Metastatic, Skin 1 (2%)
Islets, Pancreatic (69) (49) (46) (47) (59) (88)
Adenoma 1 (2%) 2 (3%)
Parathyroid Gland (57) (40) (33) (39) (47) (77)
Carcinoma 1 (3%)
Pituitary Gland (70) (49) (48) (47) (58) (80)
Histiocytic Sarcoma 1 (1%)
Pars Distalis, Adenoma 7 (10%) 12 (24%) 5 (10%) 4 (9%)
Thyroid Gland (69) (49) (49) (49) (59) (88)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Follicular Cell, Adenoma 1 (1%) 1 (2%) 1 (2%) 2 (4%) 2 (3%) 1 (1%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (69) (59) (58) (70) (70) (89)
Adenoma 2 (3%) 4 (7%) 1 (2%) 3 (4%) 1 (1%) 1 (1%)
Carcinoma 1 (1%)
Granular Cell Tumor Benign 1 (2%)
Granulosa Cell Tumor Malignant 3 (4%) 3 (4%)
Granulosa Cell Tumor Benign 1 (1%) 1 (2%) 7 (10%) 9 (13%) 7 (8%)
Hemangioma 1 (1%) 2 (3%)
Histiocytic Sarcoma 2 (3%) 2 (3%) 2 (3%) 3 (4%) 1 (1%)
Leiomyosarcoma, Metastatic, Intestine Small 1 (1%)
Leiomyosarcoma, Metastatic, Stomach 1 (1%)
Luteoma 1 (1%)
Mixed Tumor Benign 2 (3%) 6 (9%) 1 (1%)
Thecoma Benign 1 (1%)
Bilateral, Granulosa Cell Tumor Benign 1 (1%)
Uterus (70) (50) (60) (69) (70) (88)
Adenocarcinoma 1 (2%) 2 (3%) 1 (1%)
Hemangioma 1 (1%) 1 (2%) 1 (1%)
Histiocytic Sarcoma 2 (3%) 1 (1%) 1 (1%) 1 (1%)
Leiomyoma 1 (1%)
Leiomyosarcoma 1 (2%) 1 (2%)
Polyp Stromal 4 (6%) 2 (4%) 3 (4%) 1 (1%) 4 (5%)
Sarcoma 1 (2%)
Sarcoma Stromal 1 (1%)
Cervix, Hemangiosarcoma 1 (1%)
Vagina (3)
Hemangiosarcoma 1 (33%)
Leiomyosarcoma 1 (33%)
Squamous Cell Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (49) (48) (59) (70) (89)
Hemangioma 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Histiocytic Sarcoma 1 (1%) 1 (2%) 1 (2%) 4 (6%) 2 (2%)
Lymph Node (70) (50) (50) (60) (69) (89)
Histiocytic Sarcoma 1 (1%)
Axillary, Sarcoma, Metastatic, Skin 1 (1%)
Iliac, Histiocytic Sarcoma 1 (2%)
Pancreatic, Histiocytic Sarcoma 1 (1%)
Pancreatic, Leiomyosarcoma, Metastatic,
Stomach 1 (1%)
Renal, Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymph Node, Bronchial (58) (42) (42) (41) (46) (62)
Page 5
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Adenocarcinoma, Metastatic, Lung 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Carcinoma, Metastatic, Ovary 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Histiocytic Sarcoma 2 (3%) 3 (7%) 1 (2%) 3 (7%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mandibular (53) (42) (46) (49) (54) (64)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 3 (7%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mediastinal (39) (29) (33) (44) (51) (74)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 2 (4%) 2 (3%)
Carcinoma, Metastatic, Ovary 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 2 (5%) 1 (3%) 1 (3%) 1 (2%) 3 (6%) 1 (1%)
Sarcoma, Metastatic, Mammary Gland 1 (1%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%)
Lymph Node, Mesenteric (69) (46) (48) (58) (66) (81)
Carcinoma, Metastatic, Ovary 1 (2%)
Histiocytic Sarcoma 2 (3%) 2 (4%) 5 (10%) 3 (5%) 6 (9%) 4 (5%)
Leiomyosarcoma, Metastatic, Intestine Small 1 (2%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%)
Spleen (69) (49) (48) (58) (70) (88)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (3%) 1 (2%) 1 (1%)
Histiocytic Sarcoma 2 (3%) 2 (4%) 4 (8%) 3 (5%) 4 (6%) 4 (5%)
Thymus (66) (46) (45) (51) (59) (81)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (1%)
Histiocytic Sarcoma 2 (3%) 3 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (69) (46) (49) (61) (58) (87)
Adenoacanthoma 1 (2%) 2 (4%) 6 (10%) 4 (7%)
Adenocarcinoma 2 (4%) 2 (4%) 6 (10%) 12 (21%) 13 (15%)
Adenocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (1%)
Mixed Tumor Malignant 4 (5%)
Sarcoma 1 (1%)
Skin (70) (50) (50) (53) (60) (89)
Keratoacanthoma 1 (1%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Page 6
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (1%) 2 (4%) 2 (4%) 1 (2%) 2 (3%) 2 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Multiple 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Metastatic, Heart 2 (2%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (2%) 1 (1%)
Subcutaneous Tissue, Sarcoma 1 (1%) 2 (4%) 2 (4%) 5 (9%) 3 (5%) 2 (2%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (1%)
Subcutaneous Tissue, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (1%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (70) (50) (50) (50) (60) (90)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Skeletal Muscle (1) (1) (1) (2) (2)
Adenocarcinoma, Metastatic, Lung 1 (100%)
Hemangiosarcoma, Metastatic, Spleen 1 (100%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
Diaphragm, Leiomyosarcoma, Metastatic,
Intestine Small 1 (100%)
Diaphragm, Sarcoma, Metastatic, Skin 1 (50%)
Diaphragm, Sarcoma, Metastatic, Stomach 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (50) (50) (50) (60) (90)
Hemangiosarcoma, Metastatic, Heart 2 (3%) 1 (1%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 2 (4%) 4 (7%) 1 (1%)
Spinal Cord (1) (9)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (60) (60) (70) (70) (88)
Adenocarcinoma 1 (2%) 2 (3%) 2 (3%)
Adenocarcinoma, Multiple 1 (2%) 1 (1%)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) 1 (1%)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%) 1 (1%) 3 (4%) 5 (6%)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Alveolar/Bronchiolar Adenoma 4 (6%) 11 (18%) 9 (15%) 16 (23%) 13 (19%) 15 (17%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (5%) 4 (6%) 5 (7%) 4 (5%)
Page 7
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Alveolar/Bronchiolar Carcinoma 3 (5%) 10 (17%) 5 (7%) 9 (13%) 5 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%) 10 (14%) 3 (3%)
Carcinoma, Metastatic, Ovary 1 (1%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Granulosa Cell Tumor Malignant, Metastatic,
Ovary 1 (1%) 1 (1%)
Hemangiosarcoma, Metastatic, Heart 6 (9%) 15 (17%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 5 (8%) 2 (3%) 3 (4%) 1 (1%)
Histiocytic Sarcoma 2 (3%) 2 (3%) 5 (8%) 3 (4%) 7 (10%) 4 (5%)
Mixed Tumor Malignant, Metastatic, Mammary
Gland 3 (3%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Sarcoma, Metastatic, Skin 1 (1%) 1 (1%) 1 (1%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%)
Fat, Mediastinum, Hemangioma 1 (2%)
Mediastinum, Adenocarcinoma, Metastatic, Lung 1 (2%) 2 (3%) 1 (1%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (1%) 2 (3%) 3 (3%)
Mediastinum, Hemangiosarcoma, Metastatic,
Heart 1 (1%) 2 (3%) 1 (1%)
Mediastinum, Hemangiosarcoma, Metastatic,
Skin 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Mediastinum, Leiomyosarcoma, Metastatic,
Uterus 1 (2%)
Mediastinum, Mixed Tumor Malignant,
Metastatic, Mammary Gland 1 (1%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (1%) 1 (1%)
Mediastinum, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (1%)
Nose (70) (49) (48) (50) (60) (89)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (64) (50) (49) (59) (60) (73)
Adenocarcinoma 1 (2%) 1 (2%) 1 (2%)
Adenoma 10 (16%) 10 (20%) 7 (14%) 14 (24%) 21 (35%) 10 (14%)
Bilateral, Adenoma 1 (2%) 2 (3%) 2 (3%)
Zymbal's Gland (2)
Adenoma 1 (50%)
Carcinoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (69) (49) (48) (50) (60) (90)
Adenocarcinoma, Metastatic, Lung 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (1%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (2%) 1 (1%)
Histiocytic Sarcoma 2 (3%) 2 (4%) 5 (10%) 2 (4%) 5 (8%) 4 (4%)
Leiomyosarcoma, Metastatic, Stomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%)
Renal Tubule, Adenoma 2 (3%)
Urinary Bladder (67) (46) (48) (46) (59) (85)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(70) *(70) *(70) *(70) *(90)
Histiocytic Sarcoma 3 (4%) 2 (3%) 7 (10%) 4 (6%) 7 (10%) 4 (4%)
Leukemia Granulocytic 1 (1%)
Lymphoma Malignant 1 (1%) 1 (1%)
Lymphoma Malignant Lymphocytic 2 (3%) 3 (4%) 6 (9%) 3 (4%) 9 (13%) 32 (36%)
Lymphoma Malignant Mixed 5 (7%) 9 (13%) 4 (6%) 2 (3%) 1 (1%)
Lymphoma Malignant Undifferentiated Cell 1 (1%) 1 (1%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 625 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 49 44 54 61 77
Total Primary Neoplasms 65 97 93 146 191 169
Total Animals with Benign Neoplasms 33 38 25 44 47 41
Total Benign Neoplasms 46 57 41 81 92 63
Total Animals with Malignant Neoplasms 16 32 40 42 56 74
Total Malignant Neoplasms 19 40 52 65 99 106
Total Animals with Metastatic Neoplasms 2 5 12 12 22 33
Total Metastatic Neoplasm 5 11 23 27 54 94
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 70 70 70 70 50
Scheduled Sacrifice 20 20 20 20 20
Early Deaths
Dead 6 5 11 12 23 12
Moribund 9 6 15 15 23 29
Survivors
Terminal Sacrifice 35 39 24 22 3 9
Dead 1
Missing 1
Animals Examined Microscopically 70 70 70 70 70 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (64) (47) (39) (36) (42) (40)
Intestine Large, Colon (70) (47) (45) (46) (55) (44)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Intestine Small, Duodenum (67) (46) (42) (44) (47) (42)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (68) (48) (43) (46) (47) (44)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (68) (46) (43) (44) (43) (43)
Carcinoma 1 (2%) 1 (2%) 1 (2%) 2 (5%)
Liver (70) (61) (61) (60) (68) (49)
Adenocarcinoma, Metastatic, Lung 1 (1%)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 2 (3%)
Hemangiosarcoma, Metastatic, Heart 3 (5%) 9 (13%) 4 (8%)
Hepatocellular Carcinoma 8 (11%) 13 (21%) 10 (16%) 11 (18%) 18 (26%) 9 (18%)
Hepatocellular Carcinoma, Multiple 3 (4%) 4 (7%) 6 (10%) 6 (10%) 9 (13%) 5 (10%)
Hepatocellular Adenoma 17 (24%) 12 (20%) 16 (26%) 14 (23%) 22 (32%) 15 (31%)
Hepatocellular Adenoma, Multiple 2 (3%) 1 (2%) 8 (13%) 5 (8%) 7 (10%) 12 (24%)
Hepatocholangiocarcinoma 1 (1%) 1 (1%)
Histiocytic Sarcoma 4 (7%) 5 (8%) 7 (10%) 4 (8%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (1%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (1%)
Mesentery (6) (5) (9) (14) (10) (13)
Fat, Adenocarcinoma, Metastatic, Lung 1 (10%)
Fat, Hemangioma 2 (14%) 2 (15%)
Fat, Hemangioma, Multiple 1 (8%)
Fat, Hemangiosarcoma 1 (8%)
Fat, Hemangiosarcoma, Metastatic, Heart 1 (7%) 2 (15%)
Fat, Hemangiosarcoma, Metastatic, Spleen 1 (10%)
Page 11
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fat, Histiocytic Sarcoma 1 (7%) 3 (30%)
Fat, Mast Cell Tumor NOS, Metastatic, Bone
Marrow 2 (15%)
Fat, Sarcoma, Metastatic, Skin 1 (17%)
Pancreas (70) (49) (49) (58) (66) (46)
Acinus, Hemangiosarcoma, Metastatic, Heart 1 (2%)
Acinus, Histiocytic Sarcoma 1 (2%) 2 (4%)
Acinus, Sarcoma, Metastatic, Skin 1 (1%)
Duct, Adenoma, Multiple 1 (2%)
Pharynx (1) (1) (1)
Palate, Mast Cell Tumor NOS, Metastatic,
Bone Marrow 1 (100%)
Salivary Glands (70) (50) (50) (48) (58) (48)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (70) (50) (60) (60) (68) (48)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (1%) 1 (1%) 3 (6%)
Sarcoma, Metastatic, Skin 1 (1%)
Squamous Cell Carcinoma 2 (3%)
Squamous Cell Papilloma 1 (1%) 1 (2%) 7 (10%) 2 (4%)
Squamous Cell Papilloma, Multiple 1 (2%)
Stomach, Glandular (70) (48) (60) (60) (65) (44)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (70) (50) (60) (58) (68) (50)
Adenocarcinoma, Metastatic, Lung 2 (3%) 2 (3%)
Hemangiosarcoma 1 (2%) 5 (9%) 21 (31%) 15 (30%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (4%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (70) (49) (50) (47) (58) (45)
Adenoma 1 (1%) 4 (8%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Bilateral, Adenoma 1 (1%)
Adrenal Gland, Medulla (70) (48) (47) (44) (54) (45)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (70) (49) (49) (58) (65) (46)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (69) (47) (47) (48) (56) (44)
Pars Distalis, Adenoma 1 (1%)
Page 12
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (70) (50) (50) (48) (57) (48)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Follicular Cell, Adenoma 2 (3%) 4 (8%) 4 (8%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (70) (50) (50) (48) (59) (49)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Preputial Gland (8) (2) (4) (9) (6) (8)
Carcinoma 5 (83%)
Hemangiosarcoma 1 (11%)
Bilateral, Carcinoma 1 (13%)
Prostate (67) (50) (48) (45) (56) (44)
Seminal Vesicle (70) (48) (47) (46) (54) (44)
Hemangioma 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Testes (70) (50) (51) (48) (69) (50)
Hemangioma 1 (2%)
Interstitial Cell, Adenoma 1 (1%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (50) (50) (58) (69) (50)
Histiocytic Sarcoma 1 (2%) 2 (3%) 4 (6%) 3 (6%)
Mast Cell Tumor NOS 1 (1%) 1 (1%) 3 (6%)
Lymph Node (70) (50) (50) (57) (68) (50)
Hemangioma 1 (1%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (1%) 1 (2%)
Iliac, Histiocytic Sarcoma 1 (2%) 1 (2%)
Pancreatic, Histiocytic Sarcoma 1 (2%)
Lymph Node, Bronchial (64) (42) (42) (40) (46) (43)
Adenocarcinoma, Metastatic, Lung 1 (2%) 2 (5%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (5%) 3 (7%) 2 (5%)
Lymph Node, Mandibular (55) (39) (38) (37) (53) (42)
Histiocytic Sarcoma 1 (3%) 1 (3%) 2 (4%) 2 (5%)
Page 13
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%) 2 (5%)
Sarcoma, Metastatic, Skin 1 (3%)
Lymph Node, Mediastinal (37) (27) (33) (39) (48) (39)
Adenocarcinoma, Metastatic, Lung 2 (5%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 2 (6%) 1 (3%) 4 (8%) 1 (3%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 2 (5%)
Lymph Node, Mesenteric (68) (47) (47) (55) (65) (44)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Histiocytic Sarcoma 3 (6%) 4 (7%) 6 (9%) 4 (9%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Spleen (70) (50) (51) (58) (66) (47)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Histiocytic Sarcoma 4 (8%) 4 (7%) 6 (9%) 4 (9%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%) 2 (4%)
Thymus (66) (43) (42) (51) (55) (41)
Adenocarcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%) 2 (5%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (70) (50) (51) (49) (60) (50)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Sebaceous Gland, Adenoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Adenocarcinoma,
Metastatic, Lung 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%) 3 (5%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Metastatic, Heart 2 (4%)
Subcutaneous Tissue, Leiomyosarcoma 1 (2%)
Subcutaneous Tissue, Mast Cell Tumor NOS 1 (2%)
Subcutaneous Tissue, Mixed Tumor Malignant 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (1%)
Subcutaneous Tissue, Head, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 14
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (2) (2)
Adenocarcinoma, Metastatic, Lung 2 (100%)
Hemangiosarcoma 1 (50%) 1 (50%)
Diaphragm, Adenocarcinoma, Metastatic, Lung 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (50) (50) (48) (60) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Glioma Malignant 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 5 (8%) 2 (4%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (52) (62) (69) (70) (50)
Adenocarcinoma 1 (2%) 2 (3%) 4 (6%)
Adenocarcinoma, Multiple 1 (2%)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) 2 (3%) 2 (3%) 2 (4%)
Alveolar/Bronchiolar Adenoma 14 (20%) 15 (29%) 11 (18%) 20 (29%) 18 (26%) 16 (32%)
Alveolar/Bronchiolar Adenoma, Multiple 4 (6%) 6 (12%) 6 (9%) 8 (11%) 8 (16%)
Alveolar/Bronchiolar Carcinoma 4 (6%) 6 (12%) 7 (11%) 9 (13%) 12 (17%) 13 (26%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%) 2 (3%) 2 (3%) 12 (17%) 9 (18%)
Carcinoma, Metastatic, Liver 1 (1%)
Hemangiosarcoma, Metastatic, Heart 3 (4%) 8 (11%) 3 (6%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Hepatocellular Carcinoma, Metastatic 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (4%) 3 (6%) 4 (6%) 3 (4%) 4 (6%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (1%)
Histiocytic Sarcoma 4 (6%) 4 (6%) 7 (10%) 4 (8%)
Leiomyosarcoma, Metastatic, Skin 1 (1%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Sarcoma, Metastatic, Skin 1 (1%) 1 (2%)
Mediastinum, Adenocarcinoma, Metastatic, Lung 2 (3%) 3 (4%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (1%)
Mediastinum, Hemangiosarcoma, Metastatic,
Heart 3 (4%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (1%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
Nose (70) (50) (50) (47) (59) (49)
Histiocytic Sarcoma 1 (2%)
Page 15
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Leiomyosarcoma, Metastatic, Skin 1 (2%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (63) (59) (60) (57) (61) (48)
Adenocarcinoma 1 (2%) 1 (2%) 3 (5%) 2 (3%) 2 (4%)
Adenoma 6 (10%) 7 (12%) 10 (17%) 21 (37%) 26 (43%) 22 (46%)
Leiomyosarcoma, Metastatic, Skin 1 (2%)
Bilateral, Adenoma 2 (4%) 7 (11%) 4 (8%)
Zymbal's Gland (2) (1)
Adenoma 1 (50%)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (53) (54) (50) (69) (48)
Adenocarcinoma, Metastatic, Harderian Gland 1 (1%)
Adenocarcinoma, Metastatic, Lung 2 (4%) 1 (1%)
Hemangiosarcoma, Metastatic, Heart 1 (2%) 1 (2%) 2 (3%) 1 (2%)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 1 (2%) 3 (6%) 6 (9%) 2 (4%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (1%) 1 (2%)
Renal Tubule, Adenocarcinoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 2 (4%) 1 (1%) 4 (8%)
Urinary Bladder (70) (48) (50) (49) (58) (43)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(70) *(70) *(70) *(70) *(50)
Histiocytic Sarcoma 4 (6%) 5 (7%) 7 (10%) 5 (10%)
Lymphoma Malignant 1 (1%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (1%)
Lymphoma Malignant Lymphocytic 2 (3%) 2 (3%) 4 (6%) 2 (3%) 6 (12%)
Lymphoma Malignant Mixed 2 (3%) 1 (1%) 2 (3%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 1 (1%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 16
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 6.25 PPM 20 PPM 62.5 PPM 200 PPM 200 PPM
SE40
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 51 42 52 54 58 49
Total Primary Neoplasms 77 83 88 138 204 167
Total Animals with Benign Neoplasms 42 36 41 45 52 41
Total Benign Neoplasms 52 52 46 82 101 94
Total Animals with Malignant Neoplasms 20 27 34 43 50 43
Total Malignant Neoplasms 24 31 41 56 102 70
Total Animals with Metastatic Neoplasms 6 5 9 13 20 14
Total Metastatic Neoplasm 16 5 14 29 53 48
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 1 1 3
Total Uncertain Neoplasms 1 1 1 3
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 17
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 90 50 50
Scheduled Sacrifice 17
Early Deaths
Moribund 25 33 25 22
Dead 24 39 19 28
Accident 1 1
Survivors
Terminal Sacrifice 1 5
Animals Examined Microscopically 50 90 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (27) (57) (32) (32)
Intestine Large, Cecum (41) (72) (39) (42)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Duodenum (38) (67) (35) (32)
Intestine Small, Ileum (40) (68) (37) (40)
Histiocytic Sarcoma 1 (3%) 1 (3%)
Intestine Small, Jejunum (37) (65) (40) (41)
Carcinoma 1 (3%)
Hemangiosarcoma, Metastatic, Heart 1 (3%)
Histiocytic Sarcoma 1 (3%) 1 (3%) 1 (2%)
Liver (50) (89) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Hemangiosarcoma, Metastatic, Heart 18 (36%) 3 (3%) 2 (4%) 5 (10%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 8 (16%) 3 (3%) 7 (14%) 3 (6%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (1%) 7 (14%) 1 (2%)
Hepatocellular Adenoma 10 (20%) 6 (7%) 14 (29%) 7 (14%)
Hepatocellular Adenoma, Multiple 9 (18%) 3 (3%) 5 (10%) 4 (8%)
Histiocytic Sarcoma 5 (10%) 4 (4%) 2 (4%) 2 (4%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 3 (6%) 1 (1%) 1 (2%)
Mesentery (13) (6) (11) (4)
Adenocarcinoma, Metastatic, Pancreas 1 (8%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (17%)
Fat, Hemangioma 2 (18%)
Fat, Hemangiosarcoma 1 (9%)
Fat, Hemangiosarcoma, Metastatic, Heart 7 (54%) 1 (17%)
Fat, Histiocytic Sarcoma 1 (25%)
Page 18
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fat, Squamous Cell Carcinoma, Metastatic,
Stomach 2 (15%) 1 (17%) 2 (18%) 1 (25%)
Pancreas (49) (89) (46) (49)
Acinus, Adenocarcinoma 1 (2%)
Acinus, Hemangiosarcoma, Metastatic, Heart 1 (2%)
Acinus, Hemangiosarcoma, Metastatic, Liver 1 (2%)
Acinus, Histiocytic Sarcoma 1 (2%) 2 (2%) 1 (2%) 1 (2%)
Acinus, Squamous Cell Carcinoma, Metastatic,
Stomach 1 (2%) 1 (1%) 1 (2%)
Pharynx (2) (2)
Carcinoma, Metastatic, Zymbal's Gland 1 (50%)
Squamous Cell Carcinoma 1 (50%)
Squamous Cell Papilloma 1 (50%)
Salivary Glands (48) (86) (50) (50)
Histiocytic Sarcoma 1 (1%)
Stomach, Forestomach (48) (89) (50) (50)
Histiocytic Sarcoma 1 (1%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Squamous Cell Carcinoma 5 (10%) 4 (4%) 4 (8%) 6 (12%)
Squamous Cell Papilloma 4 (8%) 4 (4%) 3 (6%) 4 (8%)
Squamous Cell Papilloma, Multiple 1 (2%)
Stomach, Glandular (47) (83) (44) (47)
Histiocytic Sarcoma 1 (1%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 2 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (90) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Hemangiosarcoma 33 (66%) 7 (8%) 7 (14%) 13 (26%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (90) (50) (50)
Adenocarcinoma, Metastatic, Pancreas 1 (2%)
Bilateral, Adenoma 1 (2%)
Adrenal Gland, Medulla (48) (86) (49) (48)
Adenocarcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma 1 (1%) 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (1%) 2 (4%)
Islets, Pancreatic (49) (87) (45) (48)
Adenoma 1 (2%)
Page 19
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Parathyroid Gland (44) (69) (33) (37)
Pituitary Gland (43) (78) (43) (43)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Thyroid Gland (49) (86) (50) (49)
Follicular Cell, Adenoma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (87) (49) (50)
Adenocarcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma 1 (1%)
Preputial Gland (4) (2) (10) (6)
Adenoma 1 (10%)
Carcinoma 3 (75%) 3 (30%) 2 (33%)
Bilateral, Carcinoma 1 (25%) 1 (10%) 1 (17%)
Prostate (48) (83) (48) (47)
Seminal Vesicle (47) (84) (42) (47)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (1%)
Testes (50) (89) (50) (50)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (90) (48) (49)
Histiocytic Sarcoma 2 (4%) 4 (4%) 1 (2%) 1 (2%)
Mast Cell Tumor NOS 1 (2%) 1 (2%)
Lymph Node (50) (90) (49) (50)
Histiocytic Sarcoma 1 (1%)
Axillary, Hemangiosarcoma, Metastatic, Heart 1 (2%)
Inguinal, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Renal, Histiocytic Sarcoma 1 (2%) 1 (2%)
Renal, Squamous Cell Carcinoma, Metastatic,
Stomach 1 (2%)
Lymph Node, Bronchial (37) (53) (40) (41)
Adenocarcinoma, Metastatic, Lung 1 (3%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (3%) 1 (2%)
Page 20
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 3 (8%) 1 (3%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (3%) 1 (2%)
Lymph Node, Mandibular (31) (70) (39) (43)
Histiocytic Sarcoma 2 (3%) 2 (5%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Squamous Cell Carcinoma, Metastatic, Pharynx 1 (2%)
Lymph Node, Mediastinal (41) (68) (39) (44)
Adenocarcinoma, Metastatic, Lung 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (2%)
Histiocytic Sarcoma 4 (10%) 1 (1%) 1 (3%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (5%) 1 (1%) 2 (5%) 2 (5%)
Lymph Node, Mesenteric (44) (84) (43) (48)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Histiocytic Sarcoma 6 (14%) 3 (4%) 2 (5%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 3 (7%) 1 (1%) 1 (2%)
Spleen (48) (87) (49) (50)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Heart 3 (6%)
Histiocytic Sarcoma 4 (8%) 4 (5%) 2 (4%) 2 (4%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Thymus (37) (78) (37) (40)
Histiocytic Sarcoma 1 (3%) 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (90) (50) (50)
Sebaceous Gland, Adenoma 2 (4%) 2 (4%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Metastatic, Heart 4 (8%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (1%)
Subcutaneous Tissue, Leiomyosarcoma 1 (2%)
Subcutaneous Tissue, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (90) (50) (50)
Neuroblastoma Malignant, Metastatic, Brain 1 (2%)
Skeletal Muscle (1) (2) (2)
Abdominal, Squamous Cell Carcinoma,
Page 21
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - cont
Metastatic, Stomach 1 (50%)
Diaphragm, Hemangiosarcoma, Metastatic, Liver 1 (50%)
Diaphragm, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (90) (50) (50)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
Hemangiosarcoma, Metastatic, Heart 5 (10%)
Histiocytic Sarcoma 2 (4%) 2 (2%) 1 (2%) 1 (2%)
Olfactory Lobe, Glioma Malignant 2 (4%) 1 (2%)
Olfactory Lobe, Neuroblastoma Malignant 2 (4%)
Spinal Cord (12) (1) (2)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (90) (50) (50)
Adenocarcinoma 1 (2%) 1 (1%)
Adenocarcinoma, Multiple 1 (2%)
Adenocarcinoma, Metastatic, Harderian Gland 2 (4%) 3 (6%)
Alveolar/Bronchiolar Adenoma 14 (28%) 6 (7%) 11 (22%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 12 (24%) 4 (4%) 6 (12%) 5 (10%)
Alveolar/Bronchiolar Carcinoma 9 (18%) 5 (6%) 12 (24%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 6 (12%) 5 (10%) 5 (10%)
Carcinoma, Metastatic, Preputial Gland 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Heart 18 (36%) 2 (2%) 1 (2%) 3 (6%)
Hemangiosarcoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 5 (10%)
Histiocytic Sarcoma 5 (10%) 3 (3%) 2 (4%) 2 (4%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (1%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 1 (1%) 1 (2%) 1 (2%)
Mediastinum, Adenocarcinoma, Metastatic, Lung 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%)
Mediastinum, Carcinoma, Metastatic, Zymbal's
Gland 1 (2%)
Mediastinum, Hemangiosarcoma, Metastatic,
Heart 1 (2%) 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
Nose (49) (88) (50) (50)
Page 22
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Histiocytic Sarcoma 1 (1%)
Neuroblastoma Malignant, Metastatic, Brain 1 (2%)
Trachea (47) (84) (48) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (4) (6) (4) (3)
Adenocarcinoma, Metastatic, Harderian Gland 1 (25%)
Harderian Gland (48) (53) (42) (36)
Adenocarcinoma 1 (2%) 4 (10%)
Adenoma 20 (42%) 7 (13%) 13 (31%) 10 (28%)
Bilateral, Adenocarcinoma 1 (2%)
Bilateral, Adenoma 8 (17%) 2 (4%) 7 (17%) 3 (8%)
Zymbal's Gland (3) (2)
Carcinoma 2 (67%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (90) (50) (50)
Adenocarcinoma, Metastatic, Pancreas 1 (2%)
Adenoma 1 (2%) 1 (1%)
Hemangiosarcoma, Metastatic, Heart 6 (12%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 4 (8%) 4 (4%) 2 (4%) 2 (4%)
Mast Cell Tumor NOS, Metastatic, Bone Marrow 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%) 1 (2%) 1 (2%)
Renal Tubule, Adenoma 2 (4%) 1 (2%) 1 (2%)
Urinary Bladder (47) (83) (46) (48)
Hemangioma 1 (2%)
Histiocytic Sarcoma 2 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(90) *(50) *(50)
Histiocytic Sarcoma 7 (14%) 4 (4%) 2 (4%) 2 (4%)
Lymphoma Malignant 1 (2%) 1 (1%)
Lymphoma Malignant Lymphocytic 4 (8%) 52 (58%) 17 (34%) 30 (60%)
Lymphoma Malignant Mixed 3 (6%) 1 (1%) 5 (10%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 23
NTP Experiment-Test: 05134-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,3 BUTADIENE (BUTADIENE) Date: 09/17/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:36:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 312 PPM 625 PPM 625 PPM 625 PPM
SE52 SE13 SE 26
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 74 49 49
Total Primary Neoplasms 174 114 160 120
Total Animals with Benign Neoplasms 41 21 34 22
Total Benign Neoplasms 85 35 73 41
Total Animals with Malignant Neoplasms 50 66 49 49
Total Malignant Neoplasms 88 79 87 78
Total Animals with Metastatic Neoplasms 33 6 16 13
Total Metastatic Neoplasm 98 20 32 43
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 1
Total Uncertain Neoplasms 1 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 24
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------